Modern treatments for GERD effective at achieving long-term remission for most patients

In an evaluation of contemporary antireflux therapies for chronic gastroesophageal reflux disease (GERD), most patients who received treatment with either the proton pump inhibitor esomeprazole or laparoscopic antireflux surgery achieved and remained in disease remission for 5 years, according to a study in the May 18 issue of JAMA.

"GERD is a highly prevalent disorder caused by the reflux of gastric contents into the esophagus. It is a chronic, relapsing disease that negatively affects patients' health-related quality of life and reduces ," according to background information in the article. Two treatment options are long-term medication (such as with a [PPI]) or surgery (laparoscopic antireflux surgery [LARS]). Some patients are reluctant to take long-term medication and may prefer to have antireflux surgery. Few studies have compared pharmaceutical treatment for GERD with LARS, particularly over a longer term.

Jean-Paul Galmiche, M.D., F.R.C.P., of Nantes University, Nantes, France, and colleagues compared for chronic GERD provided by the PPI esomeprazole (dose-adjusted when required) with standardized LARS in patients who responded well to acid-suppressive therapy. The 5-year was conducted in academic hospitals in 11 European countries between October 2001 and April 2009 among 554 patients. A total of 372 patients (192 assigned to receive esomeprazole [20 to 40 mg/d, allowing for dose adjustments]; 180 assigned to undergo LARS) completed 5-year follow-up. The primary outcome for the study was time to (for LARS, defined as need for acid suppressive therapy; for esomeprazole, inadequate symptom control after dose adjustment), expressed as estimated remission rates.

The researchers found that at 5 years, an estimated 85 percent of patients in the LARS group and an estimated 92 percent in the esomeprazole group remained in remission. The esomeprazole group showed similar levels of symptoms of heartburn and acid regurgitation from the beginning of the study up to 5 years, whereas these symptoms decreased in the LARS group after randomization.

"At 5 years, acid regurgitation was significantly worse in the esomeprazole group than in the LARS group (13 percent vs. 2 percent, respectively), although there was no significant difference between the groups in the severity of heartburn (16 percent vs. 8 percent), epigastric [an area of the abdomen] pain (18 percent vs. 18 percent), or diarrhea (15 percent vs. 16 percent). At 5 years, dysphagia [difficulty swallowing] remained significantly more common in the LARS group than in the esomeprazole group (11 percent vs. 5 percent, respectively), as did bloating (40 percent vs. 28 percent, respectively) and flatulence (57 percent vs. 40 percent, respectively)," the authors write.

Serious adverse events were reported by 28.6 percent of patients who underwent LARS and by 24.1 percent of patients in the esomeprazole group over 5 years.

"This large, multicenter randomized trial demonstrated that with modern forms of antireflux therapy, either by drug-induced acid suppression or after LARS, most remain in remission for at least 5 years," the authors conclude.

More information: JAMA. 2011;305[19]1969-1977.

add to favorites email to friend print save as pdf

Related Stories

Study compares 2 nonsurgical treatments for reflux disease

Jan 19, 2009

Two non-surgical, non-pharmacological treatments for gastroesophageal reflux disease (GERD) both appear effective in reducing medication use and improving voice and swallowing symptoms, according to a report in the January ...

Acid-reducing medicines may lead to dependency

Jul 01, 2009

Treatment with proton pump inhibitors (PPIs) for eight weeks induces acid-related symptoms like heartburn, acid regurgitation and dyspepsia once treatment is withdrawn in healthy individuals, according to a new study in Gastroenterology, th ...

Surgery for severe obesity saves lives

Aug 23, 2007

An extensive swedish study from the Sahlgrenska Academy has established that surgery reduces premature death in patients with severe obesity. A long-term follow up has shown that mortality is significantly lower among patients ...

Recommended for you

Liberia closes borders and steps up Ebola screening

3 minutes ago

Liberian President Ellen Johnson Sirleaf has announced the closure of most of the Ebola-hit country's land borders, with stringent medical checks being stepped up at airports and major trade routes.

Global impact of the Ebola outbreak

2 hours ago

The Ebola virus has been spreading in West Africa since March, but the current outbreak over the past few weeks has reached new heights and elevated the crisis. More than 650 people have died, and in recent days it was learned ...

S.Korea detects second foot-and-mouth case

4 hours ago

South Korea on Monday reported its second case of foot-and-mouth disease in less than a week, triggering fearful memories of a devastating 2011 outbreak that forced the culling of millions of livestock.

User comments